Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04090775 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
A Phase 2 study, sponsored by Rampart Health, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04090775 is a Phase 2 study that has completed, run by Rampart Health, L.L.C.. The registered enrollment target is 12 participants.
The verdict
NCT04090775, a Phase 2 study, has completed, sponsored by Rampart Health, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
Interventions
- DRUG Cytoxan
- DRUG Yervoy Injectable Product
- PROCEDURE Cryosurgical freezing (cryosurgery)
- DRUG Opdivo Injectable Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04090775
The ClinicalTrials.gov registry entry for NCT04090775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rampart Health, L.L.C., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cytoxan is the first listed.
NCT04090775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04090775 about?
NCT04090775 is a clinical study titled "A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma". This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
What is the current status of trial NCT04090775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-06-28. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04090775?
The interventions under investigation include: Cytoxan (DRUG), Yervoy Injectable Product (DRUG), Cryosurgical freezing (cryosurgery) (PROCEDURE), Opdivo Injectable Product (DRUG).
Who is sponsoring clinical trial NCT04090775?
This trial is sponsored by Rampart Health, L.L.C., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.